by Plus Therapeutics | Jun 18, 2024 | Uncategorized
Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed...
by Plus Therapeutics | Jun 13, 2024 | Uncategorized
We are excited to have Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center join us as Vice President of Medical Affairs and Medical Director. Dr. Fuller will help lead the...
by Plus Therapeutics | Jun 10, 2024 | Uncategorized
Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled:...
by Plus Therapeutics | May 31, 2024 | Uncategorized
📣 NEW GLIOBLASTOMA PODCAST EPISODE! Link to listen: https://bit.ly/4dZjfUD Thank you to @glioblastomaakagbm by @glioblastomaresearchorg for hosting our very own Dr. Marc Hedrick, President and CEO of Plus Therapeutics in your latest episode. Dr. Hedrick brings his...
by Plus Therapeutics | May 30, 2024 | Uncategorized
In honor of #BrainTumorAwarenessMonth, we would like to reshare some great educational, support and financial resources for patients and caregivers fighting a brain tumor diagnosis. More information can be found on our website at ReSPECT-Trials.com along with...
by Plus Therapeutics | May 28, 2024 | Uncategorized
#ICYMI: Replay the #Glioblastoma Patient Webinar from last week, hosted by Dr. Al Musella. The presentation included information about the ReSPECT-GBM clinical trial’s promising targeted radiotherapeutic working to treat Recurrent Glioblastoma and included a...
Recent Comments